ImmuPharma raises ?1.5m to fund development programmes
30th Mar 2020 16:18
(Sharecast News) - Drug discovery and development company ImmuPharma announced subscriptions to raise ?1.5m through the issue of 15 million new ordinary shares at a price of 10p each on Monday.
Read moreImmuPharma and Avion to proceed with Lupuzor phase 3 trial
6th Feb 2020 15:54
(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on its activities with Avion Pharmaceuticals on Thursday, following the licence and development agreement it signed with Avion in November for the exclusive rights to 'Lupuzor' in North America.
Read moreImmuPharma says not looking to raise funds
11th Dec 2019 14:54
(Sharecast News) - AIM-listed specialist drug discovery and development company ImmuPharma insisted on Wednesday that it is not looking to raise funds.
Read moreImmuPharma shares soar as it teams up with Avion on Lupuzor
28th Nov 2019 16:26
(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced a licence and development agreement with Avion Pharmaceuticals on Thursday, for the exclusive rights to 'Lupuzor' in the United States.
Read moreImmuPharma pleased with Lupuzor open-label study results
28th Jun 2019 10:27
(Sharecast News) - Specialist drug discovery and development company ImmuPharma released the analysis of results from the open-label six month extension study from its original pivotal phase 3 trial of 'Lupuzor' on Friday.
Read moreImmupharma raises ?2.66m from subscription agreement with institutional investor
26th Jun 2019 11:15
(Sharecast News) - Drug discovery and development specialist Immupharma raised roughly £2.66m via a subscription agreement with institutional investor Lanstead Capital on Wednesday.
Read moreImmuPharma struggles to convince investors in latest update
14th Mar 2019 11:04
(Sharecast News) - Shares in ImmuPharma fell even further on Thursday, as the ailing drug development company struggled to give shareholders some reassurance about its future in an update.
Read moreImmuPharma upbeat on product from subsidiary Ureka
26th Feb 2019 12:06
(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Tuesday that on 25 February, the peer reviewed research journal Nature Communications published a fundamental scientific publication on the proprietary technology 'Urelix' from its subsidiary Ureka.
Read moreImmuPharma and Incanthera extend exclusivity period for Nucant agreement
31st Dec 2018 12:00
(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on its clinical development collaboration agreement for its 'Nucant' cancer programme on Monday, with specialist oncology development partner Incanthera.
Read moreImmupharma plots patient recruitment for Lupzor trials
7th Dec 2018 08:09
(Sharecast News) - Drug discovery and development outfit Immupharma has progressed its managed access programme on Lupzor as planned, with patient recruitment in France and the UK expected to follow the firm's analysis of regulatory processes across the EU.
Read moreImmuPharma still banking on Lupuzor even after failed trial
26th Sep 2018 13:55
(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced its interim results for the six months ended 30 June on Wednesday - a period in which its revenue remained negligible at £0.07m, but its drug candidate 'Lupuzor' demonstrated a superior response rate over placebo in its primary analysis on the full set of 202 patients.
Read moreWednesday broker round-up
26th Sep 2018 12:53
(Sharecast News) - IAG: UBS downgrades to neutral with a target price of 705p.
Read moreSunday share tips: Immupharma, PCF Bank
9th Sep 2018 10:59
(Sharecast News) - For the 'Inside the City' column in the Sunday Times, Sabah Meddings wrote a "cautionary tale" about former biotech darling Immupharma, which last year saw its shares rise 227% over a year.
Read moreImmupharma to make 'blockbuster' lupus treatment available
7th Sep 2018 08:10
(Sharecast News) - Pharmaceutical firm ImmuPharma on Friday signed an agreement for a managed access programme (MAP) for its "ground-breaking" new lupus treatment, Lupuzor.
Read moreImmuPharma trial of Lupuzor continuing smoothly
25th Jan 2017 14:33
(ShareCast News) - Specialist drug discovery and development company ImmuPharma provided further details of patient participation on Wednesday, following confirmation in December that the company had successfully completed patient recruitment into its pivotal 52-week Phase III clinical trial of Lupu
Read more